Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

BACKGROUND: The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagadeesh, Deepa, Horwitz, Steve, Bartlett, Nancy L, Kim, Youn, Jacobsen, Eric, Duvic, Madeleine, Little, Meredith, Trepicchio, William, Fenton, Keenan, Onsum, Matthew, Lisano, Julie, Advani, Ranjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Hematologic Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526494/
https://www.ncbi.nlm.nih.gov/pubmed/35948003
http://dx.doi.org/10.1093/oncolo/oyac137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526494/
https://www.ncbi.nlm.nih.gov/pubmed/35948003
http://dx.doi.org/10.1093/oncolo/oyac137

Ejemplares similares